CVS Health Corporation $CVS Shares Purchased by Granite Islands Private Wealth LLC

Granite Islands Private Wealth LLC boosted its position in shares of CVS Health Corporation (NYSE:CVS) by 185.0% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 11,769 shares of the pharmacy operator’s stock after acquiring an additional 7,639 shares during the quarter. Granite Islands Private Wealth LLC’s holdings in CVS Health were worth $1,008,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the company. Ellsworth Advisors LLC increased its holdings in CVS Health by 5.3% in the 3rd quarter. Ellsworth Advisors LLC now owns 38,943 shares of the pharmacy operator’s stock worth $3,337,000 after buying an additional 1,975 shares during the period. Neumann Capital Management LLC lifted its stake in CVS Health by 2.9% during the 3rd quarter. Neumann Capital Management LLC now owns 38,751 shares of the pharmacy operator’s stock valued at $3,321,000 after acquiring an additional 1,100 shares during the period. NFSG Corp lifted its stake in CVS Health by 954.0% during the 3rd quarter. NFSG Corp now owns 527 shares of the pharmacy operator’s stock valued at $45,000 after acquiring an additional 477 shares during the period. V Square Quantitative Management LLC boosted its holdings in shares of CVS Health by 22.6% in the 3rd quarter. V Square Quantitative Management LLC now owns 7,491 shares of the pharmacy operator’s stock valued at $642,000 after acquiring an additional 1,381 shares during the last quarter. Finally, Financial & Tax Architects LLC boosted its holdings in shares of CVS Health by 65.7% in the 3rd quarter. Financial & Tax Architects LLC now owns 4,344 shares of the pharmacy operator’s stock valued at $372,000 after acquiring an additional 1,723 shares during the last quarter. Hedge funds and other institutional investors own 80.66% of the company’s stock.

CVS Health Stock Performance

Shares of NYSE CVS opened at $92.45 on Friday. The company’s fifty day moving average price is $91.80 and its 200 day moving average price is $93.03. The company has a market capitalization of $118.25 billion, a PE ratio of 24.46, a price-to-earnings-growth ratio of 0.84 and a beta of 0.60. CVS Health Corporation has a 1 year low of $69.51 and a 1 year high of $110.68. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.66 and a current ratio of 0.87.

CVS Health (NYSE:CVS) last announced its quarterly earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share for the quarter, beating the consensus estimate of $1.87 by $0.71. The firm had revenue of $106.10 billion during the quarter, compared to analyst estimates of $100.03 billion. CVS Health had a return on equity of 13.12% and a net margin of 1.18%. CVS Health’s revenue for the quarter was up 7.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.81 EPS. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. On average, research analysts predict that CVS Health Corporation will post 8.02 earnings per share for the current year.

CVS Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Thursday, October 22nd will be given a dividend of $0.6650 per share. The ex-dividend date is Thursday, October 22nd. This represents a $2.66 dividend on an annualized basis and a yield of 2.9%. CVS Health’s dividend payout ratio is currently 70.37%.

Analyst Ratings Changes

A number of research firms recently issued reports on CVS. UBS Group restated a “buy” rating on shares of CVS Health in a research report on Tuesday, September 22nd. Sanford C. Bernstein reaffirmed an “outperform” rating and set a $112.00 price target on shares of CVS Health in a research report on Wednesday, September 9th. Royal Bank Of Canada increased their price target on CVS Health from $107.00 to $113.00 and gave the stock an “outperform” rating in a research report on Thursday, July 9th. Robert W. Baird set a $107.00 price objective on CVS Health in a research note on Thursday, August 6th. Finally, Truist Financial boosted their price objective on CVS Health from $108.00 to $118.00 and gave the company a “buy” rating in a report on Tuesday, July 14th. Twenty equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, CVS Health has a consensus rating of “Moderate Buy” and a consensus price target of $107.80.

Key Stories Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Improving fundamentals and valuation support the stock. CVS has recently exceeded earnings and revenue expectations, while analysts cited stronger returns, rising earnings estimates and a lower valuation than Alignment Healthcare. Its Aetna turnaround is also viewed as a potential catalyst. CVS vs. ALHC: Which Medicare Advantage Stock Is the Better Pick Now?
• Positive Sentiment: Expanded care access and quality credentials reinforce CVS’s healthcare-services strategy. CVS opened its first pharmacy-focused location in the Boston area to improve access to medications, immunizations and other services. Separately, MinuteClinic received its seventh consecutive Joint Commission accreditation, with primary care available at more than 65% of its locations. CVS Pharmacy Celebrates Opening of First Pharmacy-Focused Location in Boston Area
• Neutral Sentiment: New women’s-health collaboration could support longer-term engagement. CVS is partnering with The Midlife Collective on a research study and documentary focused on women’s midlife health. The initiative may strengthen brand awareness and consumer relationships, but it is unlikely to have a near-term financial impact. CVS Health Collaborates With The Midlife Collective
• Positive Sentiment: Home-based heart monitoring expands value-added services. Signify Health, part of CVS, offers continuous heart-rhythm monitoring for eligible health-plan members, potentially enabling earlier detection of serious conditions and supporting preventive-care economics. CVS Health: Early Detection Matters
• Negative Sentiment: $315 million opioid settlement creates legal, financial and reputational pressure. CVS agreed to settle Justice Department allegations involving unlawful opioid dispensing and false claims. The company admitted no wrongdoing but will implement tighter controlled-substance oversight, adding costs and highlighting compliance risks. CVS Agrees to Pay $315M

CVS Health Company Profile

CVS Health Corp. is an integrated health care company that provides pharmacy, insurance and health services primarily in the United States. Its operations are designed to connect consumers, health plans, health care providers and pharmacy services across multiple points of care.

The company’s major businesses include CVS Pharmacy retail locations, prescription fulfillment and consumer health products; CVS Caremark, a pharmacy benefit management business; and Aetna, which offers health insurance products and related services for employers, individuals, government programs and other organizations.